Literature DB >> 23244720

Treatment of benign prostatic hyperplasia.

Luís Campos Pinheiro1, João Martins Pisco.   

Abstract

Lower urinary tract symptoms (LUTS) may be a sign of aging rather than a consequence of benign prostatic enlargement (BPE) or benign prostatic obstruction (BPO). Medical or invasive treatments should address the bothersome symptoms and the quality of life of patients. Alpha blockers and 5-alpha reductase inhibitors are most frequently used in benign prostatic hyperplasia (BPH) medical treatments, whereas Transurethral Resection of the Prostate (TURP) remains the "gold standard" for surgical treatments. Several minimal invasive treatments are emerging with promising outcomes.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23244720     DOI: 10.1053/j.tvir.2012.09.004

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  6 in total

1.  Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk.

Authors:  Xian-Tao Zeng; Qi-Sheng Yao; Hong Weng; Sheng Li; Jing-Yu Huang; Xing-Huan Wang
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

2.  Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients.

Authors:  Weiguo Huang; Zheng Huang; Guofeng Xiao; Xiang Qin
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

3.  Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study.

Authors:  Zhilei Qiu; Changcun Zhang; Xinsheng Wang; Kai Cheng; Xin Liang; Dawen Wang; Sichuan Hou; Xinsheng Wang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2017-12-29       Impact factor: 1.195

4.  Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial.

Authors:  Saturnino Napal Lecumberri; Iñigo Insausti Gorbea; Ana Sáez de Ocáriz García; Saioa Solchaga Álvarez; José Luis Cebrián Lostal; Raquel Monreal Beortegui; Pedro José Giral Villalta; Fermín Urtasun Grijalba
Journal:  Res Rep Urol       Date:  2018-02-13

5.  Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.

Authors:  Bing-Hui Li; Tong Deng; Qiao Huang; Hao Zi; Hong Weng; Xian-Tao Zeng
Journal:  Am J Mens Health       Date:  2019 Jul-Aug

6.  Stereological comparison of intraprostatic injection of alcohol and bleomycin with finasteride gavages in rats.

Authors:  Ali Eslahi; Ali Noorafshan; Ali-Reza Safarpour; Masood Sepehrimanesh; Ali Ariafara; Elham Nadimi
Journal:  Cent European J Urol       Date:  2017-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.